Pfizer (NYSE:PFE)‘s stock had its “buy” rating restated by equities research analysts at Cantor Fitzgerald in a research note issued on Monday. They currently have a $53.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 21.76% from the stock’s previous close.

Several other research firms also recently commented on PFE. BMO Capital Markets lifted their target price on shares of Pfizer from $42.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 1st. Jefferies Financial Group set a $39.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Barclays set a $40.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 29th. Morningstar set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Finally, Deutsche Bank set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, August 21st. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating and eight have assigned a buy rating to the company. Pfizer presently has an average rating of “Hold” and an average price target of $42.67.

NYSE:PFE opened at $43.53 on Monday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a one year low of $33.20 and a one year high of $45.81. The company has a market cap of $259.01 billion, a P/E ratio of 16.43, a price-to-earnings-growth ratio of 2.19 and a beta of 0.88.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.75 by $0.03. Pfizer had a net margin of 44.63% and a return on equity of 25.26%. The business had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. During the same period last year, the company earned $0.67 EPS. The firm’s revenue was up 1.0% compared to the same quarter last year. On average, analysts expect that Pfizer will post 3 earnings per share for the current fiscal year.

In other news, major shareholder Pfizer Inc bought 55,556 shares of Pfizer stock in a transaction dated Monday, October 15th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now directly owns 21,976,484 shares in the company, valued at approximately $395,576,712. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley lifted its holdings in Pfizer by 2.1% during the third quarter. Morgan Stanley now owns 55,493,846 shares of the biopharmaceutical company’s stock valued at $2,445,614,000 after purchasing an additional 1,126,612 shares during the last quarter. Legal & General Group Plc lifted its holdings in Pfizer by 1.1% during the third quarter. Legal & General Group Plc now owns 27,673,602 shares of the biopharmaceutical company’s stock valued at $1,219,562,000 after purchasing an additional 309,817 shares during the last quarter. Griffin Asset Management Inc. lifted its holdings in Pfizer by 6.4% during the third quarter. Griffin Asset Management Inc. now owns 93,615 shares of the biopharmaceutical company’s stock valued at $4,126,000 after purchasing an additional 5,594 shares during the last quarter. Towercrest Capital Management purchased a new stake in Pfizer during the third quarter valued at about $277,000. Finally, Csenge Advisory Group lifted its holdings in Pfizer by 87.4% during the third quarter. Csenge Advisory Group now owns 26,340 shares of the biopharmaceutical company’s stock valued at $1,130,000 after purchasing an additional 12,282 shares during the last quarter. Hedge funds and other institutional investors own 68.64% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.